-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tempol in Oral Mucositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tempol in Oral Mucositis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tempol in Oral Mucositis Drug Details: Tempol is under development for the...
-
Product Insights
High-Grade Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘High-Grade Glioma - Drugs In Development, 2023’, provides an overview of the High-Grade Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for High-Grade Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Gliosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Gliosarcoma - Drugs In Development, 2023’, provides an overview of the Gliosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gliosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Sepsis – Drugs In Development, 2023
Global Markets Direct’s, ‘Sepsis - Drugs In Development, 2023’, provides an overview of the Sepsis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Arrhythmias – Drugs In Development, 2023
Global Markets Direct’s, ‘Arrhythmias - Drugs In Development, 2023’, provides an overview of the Arrhythmias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arrhythmias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vebreltinib in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vebreltinib in Non-Small Cell Lung Cancer Drug Details: APL-101 (CBT-101) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vudalimab in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Head And Neck Cancer Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRV-101 in Enterovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRV-101 in Enterovirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRV-101 in Enterovirus Infections Drug Details:PRV-101 is under development for the prevention of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ENB-003 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ENB-003 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ENB-003 in Pancreatic Cancer Drug Details: ENB-003 is under development for the...